Monopar Therapeutics (NASDAQ:MNPR) Trading Up 16.3% After Analyst Upgrade

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) were up 16.3% during mid-day trading on Monday after Jones Trading upgraded the stock from a hold rating to a strong-buy rating. The company traded as high as $101.46 and last traded at $102.16. Approximately 62,918 shares traded hands during trading, an increase of 39% from the average daily volume of 45,108 shares. The stock had previously closed at $87.82.

Several other brokerages also recently issued reports on MNPR. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Wednesday, October 8th. Piper Sandler set a $95.00 price objective on Monopar Therapeutics and gave the stock an “overweight” rating in a research report on Thursday, September 25th. Oppenheimer set a $115.00 price objective on Monopar Therapeutics and gave the stock an “outperform” rating in a research report on Thursday, October 2nd. Chardan Capital lifted their price objective on Monopar Therapeutics from $60.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, September 25th. Finally, BTIG Research lifted their price objective on Monopar Therapeutics from $87.00 to $104.00 and gave the stock a “buy” rating in a research report on Thursday, September 25th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $105.67.

Insiders Place Their Bets

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 550,229 shares of the business’s stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $63.61, for a total value of $35,000,066.69. Following the completion of the transaction, the insider directly owned 272,026 shares in the company, valued at approximately $17,303,573.86. The trade was a 66.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 20.50% of the company’s stock.

Institutional Trading of Monopar Therapeutics

Several institutional investors have recently made changes to their positions in MNPR. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Monopar Therapeutics during the 2nd quarter valued at $34,000. AlphaQuest LLC purchased a new stake in shares of Monopar Therapeutics during the 1st quarter valued at $44,000. JPMorgan Chase & Co. grew its stake in shares of Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after buying an additional 1,821 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Monopar Therapeutics during the 2nd quarter valued at $80,000. Finally, New York State Common Retirement Fund purchased a new stake in shares of Monopar Therapeutics during the 2nd quarter valued at $104,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

Monopar Therapeutics Trading Up 16.2%

The company’s 50 day moving average price is $55.33 and its 200-day moving average price is $43.76. The company has a market capitalization of $629.65 million, a PE ratio of -30.65 and a beta of 1.42.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.12. As a group, analysts predict that Monopar Therapeutics Inc. will post -1.65 earnings per share for the current year.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.